Posts

Biogen Acquires Apellis for $5.6 Billion to Expand Immunology and Kidney Disease Portfolio

on

Centessa Pharmaceuticals Advances Orexin Agonist Pipeline with Key 2026 Milestones

on

White House Eyes Former Rep. Michael Burgess for CDC Leadership Amid Vaccine Politics and MAHA Tensions

on

Bristol Myers Squibb Partners with Faro to Scale AI in Clinical Trial Protocols

on

HCP Engagement Stuck in the Past: How Pre-Consult Precision Unlocks the Future

on

PepGen's PGN-EDODM1 Phase 2 Trial Shows Mixed Mid-Stage Results with One Patient Outlier

on

Enveda Biosciences Advances ENV-294 to Phase 2 Trials After Promising Phase 1b Data Rivaling Dupixent in Atopic Dermatitis

on

Merck Unveils Phase 3 Data: Oral PCSK9 Inhibitor Enlicitide Outperforms Rivals in Cholesterol Reduction

on

After Missing Kezar Buyout in 2024, Kevin Tang Returns as CEO of Aurinia with $50M Offer

on

INmune Bio Inc. Announces 2025 Results and Provides Business Update

on

Otsuka's $1.225B Acquisition of Transcend Therapeutics for PTSD Neuroplastogen TSND-201

on

Blackstone Closes Record $6.3 Billion Life Sciences Fund

on

Merck Touts Strong Comparator Data for Enlicitide Decanoate, Oral PCSK9 Inhibitor Reducing LDL-C by Up to 60% in Phase 3 Trials

on

Biopharma Bites: FDA Approves High-Dose Spinraza for SMA, J&J's $500M Autoimmune Deal, and Updates from BMS and Boehringer

on

Ainnocence's CarbonAI: Proprietary AI Engine for Small-Molecule Drug Discovery

on

Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

on

Sanofi Reports Positive but Mixed Phase 3 Results for Amlitelimab in Atopic Dermatitis with OX40L Targeting and Kaposi's Sarcoma Case

on

Merck Advances Winrevair to Phase 3 with Preference for Lower Dose in Rare Heart Failure Trial

on

Eli Lilly and Insilico Medicine Announce $2.75 Billion AI-Driven Drug Discovery Collaboration

on

Biogen Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus Erythematosus from AMETHYST Study

on

"A Bit of a Surprise": Kardigan's Tonlamarsen Shows No Blood Pressure Benefit from Repeat Dosing in Phase 2 Trial

on

AstraZeneca's Tozorakimab Achieves Phase 3 Success in Broader COPD Population

on

AstraZeneca's In Vivo CAR-T ESO-T01 Shows Promise in Multiple Myeloma with Remissions but One Death in China Trial

on

Kailera Therapeutics Files for Nasdaq IPO to Fund Obesity Drug Pipeline Licensed from China Partner

on

Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension

on

FDA Approves Novo Nordisk's Awiqli: First Once-Weekly Basal Insulin for Type 2 Diabetes

on

Recordati Confirms Non-Binding €10.9 Billion Full Takeover Offer from CVC Capital Partners

on

"We need to put some bad ideas to bed": Inside Incubate's battles for biotech on Capitol Hill

on

Novartis Agrees to Acquire Excellergy for Up to $2 Billion to Bolster Allergy Portfolio with Potential Xolair Successor

on

FDA Approves Rocket Pharma's Kresladi Gene Therapy for Ultra-Rare LAD-I After Setbacks

on

Beam's Base Editor Advances to Pivotal Development on Back of Impressive AATD Data

on

Pinnacle Medicines Secures $89M Series B Funding for Oral Peptide Pipeline

on

Kodiak Sciences' Zenkuda Succeeds in Second Phase 3 Trial for Diabetic Retinopathy

on

First Patient Dosed in Phase 1b/2 Trial of HLX701 Combination Therapy for Advanced Colorectal Cancer

on

Novo Nordisk's GLP-1 Pipeline Advances with Oral Innovations Amid Analyst Concerns on Oral Trends

on

Artera Appoints Damon Lanphear as New CTO and Promotes Nicole Ossey to SVP of People

on

FDA Clears Philips' EchoNavigator R5.0 with DeviceGuide for Real-Time AI Guidance in Minimally Invasive Mitral Valve Repair

on

Swift Medical's Swift Ray Receives FDA 510(k) Clearance for Advanced Wound Imaging

on

Medicus Pharma Business Update Call Highlights 80% ORR in Phase 2 SkinJect Study and AI-Enabled Drug Development

on

Light AI Reports Q4 and Full-Year 2025 Financial Results

on

Recent Biotech and Pharma News - March 2026

on

Outspoken ACIP Member Robert Malone Steps Down Amid Vaccine Panel Uncertainty

on

Wave Life Sciences' Obesity Drug WVE-007 Shows Strong Early Fat Loss Results, Not 1% Dip

on

Takeda Announces Leadership Transition with Julie Kim as New CEO Amid Organizational Changes

on

Recent Pharmaceutical Industry Developments: AbbVie's China Engagement and Biologics Expansion

on

FDA Approves Denali Therapeutics' Avlayah for Hunter Syndrome, First Treatment for Neurologic Manifestations

on

Pharma R&D Spend Drops 3.6% as Pipeline Prioritizations Take Shape

on

Maze Therapeutics Meets Expectations in Phase 2 HORIZON Trial for APOL1-Mediated Kidney Disease, Positioning to Challenge Vertex

on

After Tumultuous Year, Sarepta Plots Rebound with Early Data on RNA Therapies

on

FDA Approves Corcept's Lifyorli for Platinum-Resistant Ovarian Cancer Months Early

on

FDA Grants Accelerated Approval to Denali's Avlayah for Hunter Syndrome, Defying Rare Disease Rejection Trend

on

CROSSJECT Appoints Lionel Seltz as Chief Financial Officer

on

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

on

Allergan Aesthetics Reinforces Scientific Leadership with 21 Evidence-Based E-Posters at AMWC 2026

on